Handelsbanken Fonder AB Raises Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Handelsbanken Fonder AB lifted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 11.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 19,116 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,900 shares during the period. Handelsbanken Fonder AB’s holdings in Supernus Pharmaceuticals were worth $691,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Supernus Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after acquiring an additional 352 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth about $72,000. Venturi Wealth Management LLC acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth about $92,000. KBC Group NV lifted its holdings in shares of Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 929 shares during the period. Finally, Kennebec Savings Bank acquired a new stake in shares of Supernus Pharmaceuticals during the third quarter worth about $103,000.

Supernus Pharmaceuticals Trading Up 0.9 %

Shares of NASDAQ:SUPN opened at $32.06 on Friday. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The company has a market capitalization of $1.77 billion, a PE ratio of 29.96 and a beta of 0.90. The business has a 50 day moving average of $37.12 and a two-hundred day moving average of $35.35.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 700 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on SUPN shares. StockNews.com downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.